CorestemChemon, a GLP-certified preclinical CRO based in South Korea, announced on Sunday that it has entered into a strategic partnership with ATG Lifetech, a biotechnology company specialising in transcriptome analytics and organoid-based modelling.

This collaboration aims to deliver next-generation, precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures across the US, Europe and Asia.

CorestemChemon and ATG Lifetech intend to co-develop: a transcriptome-based evaluation platform for predictive drug efficacy and safety profiling; disease-relevant organoid models for liver, heart and the blood-brain barrier (BBB); a high-throughput transcriptomics analytics service for differentiating true vs. false positives in tumorigenicity studies; and shared access to regulatory-aligned expertise for global clients targeting FDA/EMA pathways.

The two companies plan to showcase their joint research outputs at a major toxicology and preclinical science conference in Q4 2025. Global service launches will follow, focused on biotech and pharmaceutical customers in need of high-content, biologically faithful preclinical testing.